 Marco Del Chiaro
Concepts (545)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 140 | 2024 | 731 | 30.330 |
Why?
| | Carcinoma, Pancreatic Ductal | 61 | 2023 | 211 | 16.250 |
Why?
| | Pancreatectomy | 56 | 2024 | 171 | 14.220 |
Why?
| | Pancreaticoduodenectomy | 28 | 2023 | 133 | 6.080 |
Why?
| | Pancreas | 36 | 2023 | 276 | 4.360 |
Why?
| | Adenocarcinoma | 18 | 2023 | 795 | 4.140 |
Why?
| | Adenocarcinoma, Mucinous | 15 | 2023 | 60 | 3.940 |
Why?
| | Neoadjuvant Therapy | 22 | 2023 | 304 | 3.710 |
Why?
| | Pancreatic Cyst | 10 | 2023 | 47 | 2.640 |
Why?
| | Pancreatic Fistula | 11 | 2023 | 21 | 2.340 |
Why?
| | Carcinoma, Papillary | 9 | 2021 | 73 | 2.080 |
Why?
| | Pancreatic Ducts | 10 | 2022 | 69 | 1.930 |
Why?
| | Common Bile Duct Neoplasms | 5 | 2023 | 24 | 1.930 |
Why?
| | Ampulla of Vater | 5 | 2023 | 30 | 1.920 |
Why?
| | Humans | 210 | 2024 | 114689 | 1.740 |
Why?
| | Exocrine Pancreatic Insufficiency | 5 | 2019 | 17 | 1.680 |
Why?
| | Early Detection of Cancer | 6 | 2021 | 328 | 1.650 |
Why?
| | Retrospective Studies | 74 | 2024 | 12551 | 1.640 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2023 | 59 | 1.500 |
Why?
| | Aged | 68 | 2023 | 19074 | 1.390 |
Why?
| | Mesenteric Artery, Superior | 4 | 2020 | 12 | 1.380 |
Why?
| | Pancreas Transplantation | 24 | 2010 | 61 | 1.380 |
Why?
| | Vascular Surgical Procedures | 3 | 2021 | 259 | 1.220 |
Why?
| | Pancreatitis, Chronic | 6 | 2020 | 40 | 1.210 |
Why?
| | Portal Vein | 8 | 2021 | 76 | 1.190 |
Why?
| | Middle Aged | 75 | 2023 | 26737 | 1.180 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 8 | 2023 | 1355 | 1.160 |
Why?
| | Quality of Life | 7 | 2023 | 2353 | 1.160 |
Why?
| | Islets of Langerhans | 5 | 2020 | 726 | 1.060 |
Why?
| | Prognosis | 21 | 2023 | 3329 | 1.040 |
Why?
| | Aged, 80 and over | 39 | 2021 | 6347 | 1.030 |
Why?
| | Carcinoma, Neuroendocrine | 2 | 2023 | 29 | 1.030 |
Why?
| | Postoperative Complications | 27 | 2023 | 2128 | 1.020 |
Why?
| | Endosonography | 5 | 2021 | 140 | 1.020 |
Why?
| | Treatment Outcome | 37 | 2023 | 9088 | 0.990 |
Why?
| | Male | 90 | 2023 | 55599 | 0.980 |
Why?
| | Nomograms | 3 | 2022 | 41 | 0.970 |
Why?
| | Precancerous Conditions | 3 | 2015 | 158 | 0.960 |
Why?
| | Female | 86 | 2023 | 59511 | 0.900 |
Why?
| | Duodenal Neoplasms | 3 | 2023 | 19 | 0.900 |
Why?
| | CA-19-9 Antigen | 3 | 2022 | 14 | 0.890 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 3 | 2023 | 25 | 0.890 |
Why?
| | Mesenteric Veins | 3 | 2021 | 9 | 0.890 |
Why?
| | Biomarkers, Tumor | 11 | 2022 | 1040 | 0.820 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2020 | 154 | 0.810 |
Why?
| | Survival Rate | 11 | 2023 | 1644 | 0.800 |
Why?
| | Adult | 60 | 2022 | 30550 | 0.770 |
Why?
| | Organ Transplantation | 2 | 2023 | 159 | 0.760 |
Why?
| | Surgical Stapling | 1 | 2021 | 9 | 0.750 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2023 | 858 | 0.750 |
Why?
| | Risk Assessment | 10 | 2021 | 2968 | 0.740 |
Why?
| | Absorbable Implants | 1 | 2021 | 34 | 0.730 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 179 | 0.730 |
Why?
| | Neoplasm Invasiveness | 7 | 2020 | 442 | 0.710 |
Why?
| | Cystadenocarcinoma, Mucinous | 2 | 2018 | 14 | 0.710 |
Why?
| | Neoplasms, Second Primary | 2 | 2019 | 92 | 0.700 |
Why?
| | Vascular Neoplasms | 1 | 2020 | 15 | 0.680 |
Why?
| | Neoplasms, Multiple Primary | 3 | 2015 | 52 | 0.680 |
Why?
| | Arteries | 2 | 2019 | 247 | 0.670 |
Why?
| | Pancreatitis | 5 | 2022 | 107 | 0.670 |
Why?
| | Neoplasm Staging | 10 | 2023 | 1167 | 0.670 |
Why?
| | Adenocarcinoma, Papillary | 2 | 2017 | 9 | 0.660 |
Why?
| | Endocrine System Diseases | 1 | 2019 | 30 | 0.660 |
Why?
| | Thrombelastography | 1 | 2020 | 180 | 0.660 |
Why?
| | Neuroendocrine Tumors | 4 | 2023 | 85 | 0.650 |
Why?
| | Practice Guidelines as Topic | 3 | 2021 | 1395 | 0.640 |
Why?
| | Follow-Up Studies | 18 | 2022 | 4411 | 0.610 |
Why?
| | Chemotherapy, Adjuvant | 8 | 2023 | 332 | 0.610 |
Why?
| | Metabolomics | 2 | 2019 | 521 | 0.590 |
Why?
| | Patient Compliance | 1 | 2021 | 525 | 0.570 |
Why?
| | Europe | 8 | 2021 | 334 | 0.570 |
Why?
| | Kidney Transplantation | 17 | 2016 | 541 | 0.570 |
Why?
| | Neoplasm Metastasis | 1 | 2019 | 523 | 0.560 |
Why?
| | Living Donors | 3 | 2016 | 270 | 0.550 |
Why?
| | Hepatic Artery | 4 | 2020 | 49 | 0.540 |
Why?
| | Celiac Artery | 4 | 2020 | 9 | 0.530 |
Why?
| | Watchful Waiting | 1 | 2016 | 55 | 0.530 |
Why?
| | Evidence-Based Medicine | 4 | 2021 | 668 | 0.520 |
Why?
| | Hepatitis B virus | 1 | 2016 | 25 | 0.520 |
Why?
| | Pancreaticojejunostomy | 3 | 2022 | 5 | 0.520 |
Why?
| | Patient Selection | 8 | 2014 | 641 | 0.520 |
Why?
| | Cohort Studies | 11 | 2024 | 4895 | 0.510 |
Why?
| | Hypothermia, Induced | 1 | 2016 | 66 | 0.500 |
Why?
| | Disease Progression | 4 | 2022 | 2380 | 0.500 |
Why?
| | Pancreatic Diseases | 3 | 2020 | 64 | 0.480 |
Why?
| | Organ Sparing Treatments | 1 | 2015 | 31 | 0.480 |
Why?
| | Antineoplastic Agents | 6 | 2021 | 1879 | 0.470 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2016 | 211 | 0.460 |
Why?
| | Clinical Trials as Topic | 1 | 2018 | 932 | 0.450 |
Why?
| | Palliative Care | 3 | 2019 | 644 | 0.450 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 4 | 2019 | 180 | 0.440 |
Why?
| | Prospective Studies | 14 | 2022 | 6220 | 0.430 |
Why?
| | Cystadenocarcinoma | 1 | 2013 | 2 | 0.430 |
Why?
| | Cystadenoma | 1 | 2013 | 3 | 0.430 |
Why?
| | Tomography, X-Ray Computed | 10 | 2021 | 2286 | 0.430 |
Why?
| | Robotics | 1 | 2014 | 75 | 0.430 |
Why?
| | Autoimmune Diseases | 3 | 2021 | 382 | 0.420 |
Why?
| | Diabetes Mellitus | 3 | 2019 | 900 | 0.420 |
Why?
| | Incidence | 8 | 2019 | 2313 | 0.410 |
Why?
| | Cystadenoma, Serous | 3 | 2020 | 18 | 0.410 |
Why?
| | Italy | 11 | 2013 | 92 | 0.410 |
Why?
| | Combined Modality Therapy | 4 | 2023 | 1121 | 0.390 |
Why?
| | Diagnosis, Differential | 7 | 2022 | 1342 | 0.380 |
Why?
| | Dilatation, Pathologic | 3 | 2020 | 55 | 0.380 |
Why?
| | Risk Factors | 15 | 2023 | 8632 | 0.380 |
Why?
| | Magnetic Resonance Imaging | 8 | 2021 | 3053 | 0.370 |
Why?
| | Gastroenterology | 2 | 2023 | 159 | 0.370 |
Why?
| | Risk | 5 | 2022 | 812 | 0.360 |
Why?
| | Adolescent | 14 | 2022 | 17848 | 0.360 |
Why?
| | Gamma Rays | 2 | 2021 | 48 | 0.360 |
Why?
| | Tissue Donors | 14 | 2005 | 316 | 0.360 |
Why?
| | Sweden | 3 | 2021 | 65 | 0.350 |
Why?
| | Chemoradiotherapy | 2 | 2022 | 188 | 0.340 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2010 | 30 | 0.340 |
Why?
| | Kidney | 2 | 2016 | 1188 | 0.340 |
Why?
| | Portal System | 6 | 2020 | 13 | 0.340 |
Why?
| | Decision Making | 1 | 2016 | 782 | 0.340 |
Why?
| | Young Adult | 11 | 2022 | 10470 | 0.340 |
Why?
| | Neoplasm Grading | 4 | 2020 | 242 | 0.340 |
Why?
| | Deoxycytidine | 6 | 2023 | 138 | 0.340 |
Why?
| | Mass Screening | 2 | 2019 | 1004 | 0.330 |
Why?
| | Propensity Score | 2 | 2022 | 224 | 0.320 |
Why?
| | Age Factors | 6 | 2022 | 2894 | 0.320 |
Why?
| | Software | 2 | 2017 | 530 | 0.320 |
Why?
| | Population Surveillance | 2 | 2019 | 392 | 0.320 |
Why?
| | Benchmarking | 2 | 2020 | 161 | 0.310 |
Why?
| | Tumor Burden | 2 | 2022 | 259 | 0.310 |
Why?
| | Graft Survival | 12 | 2005 | 446 | 0.300 |
Why?
| | Fluorouracil | 5 | 2021 | 152 | 0.290 |
Why?
| | Laparoscopy | 3 | 2021 | 398 | 0.290 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2086 | 0.290 |
Why?
| | Survival Analysis | 11 | 2019 | 1211 | 0.290 |
Why?
| | Islets of Langerhans Transplantation | 3 | 2020 | 53 | 0.280 |
Why?
| | Internationality | 4 | 2020 | 143 | 0.280 |
Why?
| | Length of Stay | 5 | 2021 | 962 | 0.270 |
Why?
| | Drainage | 10 | 2022 | 151 | 0.270 |
Why?
| | Disease-Free Survival | 5 | 2023 | 620 | 0.270 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 111 | 0.270 |
Why?
| | Family Health | 1 | 2007 | 193 | 0.270 |
Why?
| | Pedigree | 3 | 2014 | 460 | 0.270 |
Why?
| | Multidetector Computed Tomography | 2 | 2016 | 26 | 0.260 |
Why?
| | Adenoma | 2 | 2020 | 189 | 0.260 |
Why?
| | Predictive Value of Tests | 4 | 2021 | 1796 | 0.260 |
Why?
| | Immunohistochemistry | 5 | 2019 | 1629 | 0.250 |
Why?
| | Cyst Fluid | 2 | 2022 | 27 | 0.250 |
Why?
| | Proportional Hazards Models | 4 | 2023 | 1075 | 0.240 |
Why?
| | Chemoradiotherapy, Adjuvant | 3 | 2019 | 40 | 0.230 |
Why?
| | Time Factors | 10 | 2021 | 6116 | 0.230 |
Why?
| | Prevalence | 3 | 2023 | 2251 | 0.230 |
Why?
| | Leucovorin | 2 | 2021 | 43 | 0.230 |
Why?
| | Liver Neoplasms | 2 | 2019 | 506 | 0.220 |
Why?
| | Pilot Projects | 5 | 2023 | 1373 | 0.220 |
Why?
| | Hospital Mortality | 4 | 2020 | 776 | 0.220 |
Why?
| | Metastasectomy | 1 | 2023 | 13 | 0.220 |
Why?
| | Incidental Findings | 2 | 2021 | 70 | 0.220 |
Why?
| | Reoperation | 7 | 2018 | 514 | 0.220 |
Why?
| | Hyperemia | 1 | 2023 | 45 | 0.210 |
Why?
| | Stomach Neoplasms | 1 | 2023 | 65 | 0.210 |
Why?
| | Surgical Oncology | 1 | 2022 | 18 | 0.210 |
Why?
| | STAT3 Transcription Factor | 2 | 2022 | 173 | 0.200 |
Why?
| | Microbiota | 2 | 2021 | 647 | 0.200 |
Why?
| | Hyperamylasemia | 1 | 2022 | 3 | 0.200 |
Why?
| | Forecasting | 1 | 2023 | 330 | 0.200 |
Why?
| | Pancreatitis, Acute Necrotizing | 1 | 2022 | 11 | 0.200 |
Why?
| | Japan | 4 | 2023 | 86 | 0.200 |
Why?
| | Multicenter Studies as Topic | 1 | 2023 | 249 | 0.200 |
Why?
| | Plastics | 1 | 2022 | 35 | 0.190 |
Why?
| | Carcinoma, Acinar Cell | 1 | 2021 | 4 | 0.190 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2022 | 76 | 0.190 |
Why?
| | Biliary Tract Surgical Procedures | 1 | 2021 | 21 | 0.190 |
Why?
| | Pathology, Clinical | 1 | 2021 | 32 | 0.190 |
Why?
| | Cysts | 1 | 2022 | 93 | 0.190 |
Why?
| | Datasets as Topic | 1 | 2021 | 100 | 0.190 |
Why?
| | ADAM10 Protein | 1 | 2021 | 28 | 0.180 |
Why?
| | Surgical Mesh | 1 | 2021 | 40 | 0.180 |
Why?
| | Fusobacterium nucleatum | 1 | 2020 | 3 | 0.180 |
Why?
| | Fusobacterium Infections | 1 | 2020 | 6 | 0.180 |
Why?
| | Digestive System Surgical Procedures | 1 | 2021 | 91 | 0.180 |
Why?
| | Amyloid Precursor Protein Secretases | 1 | 2021 | 72 | 0.180 |
Why?
| | Oligonucleotides, Antisense | 1 | 2020 | 100 | 0.170 |
Why?
| | Microdissection | 2 | 2011 | 15 | 0.170 |
Why?
| | Cyclosporine | 4 | 2005 | 161 | 0.170 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2010 | 81 | 0.170 |
Why?
| | Blood | 1 | 2020 | 96 | 0.170 |
Why?
| | Comorbidity | 2 | 2022 | 1448 | 0.170 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2020 | 56 | 0.170 |
Why?
| | Peritoneal Neoplasms | 1 | 2020 | 54 | 0.170 |
Why?
| | Antibodies, Bacterial | 1 | 2020 | 119 | 0.170 |
Why?
| | Cystadenocarcinoma, Serous | 1 | 2020 | 44 | 0.170 |
Why?
| | Conservative Treatment | 1 | 2020 | 29 | 0.170 |
Why?
| | Radiation Injuries | 1 | 2021 | 128 | 0.170 |
Why?
| | Immunosuppressive Agents | 6 | 2005 | 646 | 0.160 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2021 | 167 | 0.160 |
Why?
| | Dilatation | 1 | 2019 | 60 | 0.160 |
Why?
| | Elective Surgical Procedures | 1 | 2020 | 151 | 0.160 |
Why?
| | Lasers | 2 | 2011 | 121 | 0.160 |
Why?
| | Patient Care Team | 3 | 2020 | 517 | 0.160 |
Why?
| | Insulin | 8 | 2013 | 2080 | 0.160 |
Why?
| | Gene Expression Regulation, Neoplastic | 4 | 2019 | 1141 | 0.160 |
Why?
| | Sensitivity and Specificity | 2 | 2021 | 1693 | 0.160 |
Why?
| | Bacterial Infections | 1 | 2021 | 218 | 0.160 |
Why?
| | Saliva | 1 | 2020 | 188 | 0.160 |
Why?
| | Biliary Tract Diseases | 1 | 2019 | 32 | 0.160 |
Why?
| | Laparotomy | 2 | 2016 | 103 | 0.160 |
Why?
| | Mouth | 1 | 2019 | 70 | 0.160 |
Why?
| | Organ Culture Techniques | 1 | 2019 | 140 | 0.160 |
Why?
| | Bile Ducts | 1 | 2019 | 68 | 0.160 |
Why?
| | Fibrosis | 1 | 2021 | 453 | 0.160 |
Why?
| | Societies, Medical | 2 | 2020 | 664 | 0.150 |
Why?
| | DNA Damage | 1 | 2021 | 351 | 0.150 |
Why?
| | Nutritional Support | 1 | 2018 | 27 | 0.150 |
Why?
| | Iopamidol | 2 | 2016 | 13 | 0.150 |
Why?
| | Recombinant Fusion Proteins | 4 | 2005 | 616 | 0.150 |
Why?
| | Carcinoma | 1 | 2019 | 198 | 0.150 |
Why?
| | Jejunum | 2 | 2016 | 24 | 0.150 |
Why?
| | Radiosurgery | 1 | 2020 | 299 | 0.150 |
Why?
| | Logistic Models | 2 | 2020 | 1841 | 0.150 |
Why?
| | Malnutrition | 1 | 2018 | 62 | 0.140 |
Why?
| | DNA, Bacterial | 1 | 2019 | 311 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 2 | 2016 | 811 | 0.140 |
Why?
| | Machine Learning | 1 | 2020 | 316 | 0.140 |
Why?
| | Biliary Tract Neoplasms | 1 | 2016 | 20 | 0.140 |
Why?
| | Hyperglycemia | 1 | 2020 | 292 | 0.140 |
Why?
| | Hepatic Duct, Common | 1 | 2016 | 6 | 0.130 |
Why?
| | Epitopes | 1 | 2018 | 435 | 0.130 |
Why?
| | Sex Factors | 1 | 2022 | 1715 | 0.130 |
Why?
| | Jaundice, Obstructive | 1 | 2016 | 3 | 0.130 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2016 | 15 | 0.130 |
Why?
| | Cannabis | 1 | 2023 | 384 | 0.130 |
Why?
| | Triiodobenzoic Acids | 1 | 2016 | 11 | 0.130 |
Why?
| | Embolization, Therapeutic | 1 | 2018 | 178 | 0.130 |
Why?
| | Organ Preservation Solutions | 3 | 2005 | 39 | 0.130 |
Why?
| | Cholangitis, Sclerosing | 1 | 2016 | 66 | 0.130 |
Why?
| | Printing, Three-Dimensional | 1 | 2016 | 61 | 0.130 |
Why?
| | Surveys and Questionnaires | 4 | 2022 | 4623 | 0.130 |
Why?
| | Radiographic Image Enhancement | 1 | 2016 | 52 | 0.130 |
Why?
| | Diabetes Mellitus, Type 1 | 10 | 2010 | 3252 | 0.130 |
Why?
| | Recovery of Function | 1 | 2019 | 574 | 0.130 |
Why?
| | Hepatitis B | 1 | 2016 | 51 | 0.130 |
Why?
| | Bacteriocins | 1 | 2015 | 1 | 0.130 |
Why?
| | Organ Preservation | 3 | 2004 | 64 | 0.120 |
Why?
| | Genes, BRCA2 | 1 | 2015 | 24 | 0.120 |
Why?
| | Genes, BRCA1 | 1 | 2015 | 31 | 0.120 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 338 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2018 | 719 | 0.120 |
Why?
| | Coronavirus Infections | 1 | 2020 | 330 | 0.120 |
Why?
| | Genomics | 2 | 2017 | 635 | 0.120 |
Why?
| | Cross-Sectional Studies | 2 | 2022 | 4410 | 0.120 |
Why?
| | Membrane Proteins | 1 | 2021 | 1019 | 0.120 |
Why?
| | Papilloma, Intraductal | 1 | 2014 | 3 | 0.120 |
Why?
| | Heredity | 1 | 2014 | 12 | 0.120 |
Why?
| | Reproducibility of Results | 6 | 2019 | 2765 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2017 | 439 | 0.120 |
Why?
| | Antibodies, Monoclonal | 4 | 2005 | 1262 | 0.120 |
Why?
| | Liver Transplantation | 3 | 2013 | 707 | 0.110 |
Why?
| | Severity of Illness Index | 3 | 2019 | 2540 | 0.110 |
Why?
| | Neoplasm, Residual | 1 | 2014 | 104 | 0.110 |
Why?
| | Amylases | 1 | 2013 | 13 | 0.110 |
Why?
| | MicroRNAs | 2 | 2010 | 600 | 0.110 |
Why?
| | Risk Adjustment | 1 | 2014 | 76 | 0.110 |
Why?
| | Immunotherapy, Adoptive | 1 | 2016 | 184 | 0.110 |
Why?
| | Tissue and Organ Harvesting | 5 | 2005 | 62 | 0.110 |
Why?
| | Perception | 1 | 2016 | 311 | 0.110 |
Why?
| | Cell Proliferation | 5 | 2021 | 2187 | 0.110 |
Why?
| | Precision Medicine | 1 | 2017 | 337 | 0.110 |
Why?
| | Tacrolimus | 2 | 2005 | 134 | 0.110 |
Why?
| | Virus Diseases | 1 | 2016 | 195 | 0.110 |
Why?
| | Abdomen | 2 | 2004 | 99 | 0.110 |
Why?
| | Neoplasms | 2 | 2022 | 2097 | 0.110 |
Why?
| | Syndrome | 1 | 2014 | 333 | 0.110 |
Why?
| | Diagnostic Imaging | 1 | 2015 | 275 | 0.110 |
Why?
| | Cystadenoma, Mucinous | 1 | 2013 | 13 | 0.110 |
Why?
| | Apoptosis | 5 | 2021 | 2363 | 0.110 |
Why?
| | Insulin-Secreting Cells | 2 | 2007 | 317 | 0.110 |
Why?
| | Imaging, Three-Dimensional | 1 | 2016 | 512 | 0.100 |
Why?
| | Cadaver | 8 | 2005 | 299 | 0.100 |
Why?
| | Diagnostic Errors | 1 | 2014 | 149 | 0.100 |
Why?
| | Catheter Ablation | 1 | 2015 | 288 | 0.100 |
Why?
| | Biomarkers | 1 | 2022 | 3408 | 0.100 |
Why?
| | Endoscopy | 1 | 2014 | 246 | 0.100 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2016 | 615 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1177 | 0.100 |
Why?
| | Preoperative Care | 1 | 2014 | 319 | 0.100 |
Why?
| | C-Reactive Protein | 1 | 2013 | 362 | 0.100 |
Why?
| | Graft Rejection | 5 | 2005 | 513 | 0.090 |
Why?
| | Loss of Heterozygosity | 1 | 2011 | 40 | 0.090 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 44 | 0.090 |
Why?
| | Tissue and Organ Procurement | 2 | 2004 | 228 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2016 | 687 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2177 | 0.090 |
Why?
| | Kruppel-Like Transcription Factors | 1 | 2011 | 61 | 0.090 |
Why?
| | Glucose | 3 | 2020 | 897 | 0.090 |
Why?
| | Raffinose | 3 | 2005 | 18 | 0.090 |
Why?
| | Disaccharides | 3 | 2005 | 16 | 0.090 |
Why?
| | Mannitol | 3 | 2005 | 32 | 0.090 |
Why?
| | Allopurinol | 3 | 2005 | 53 | 0.090 |
Why?
| | Histidine | 3 | 2005 | 57 | 0.090 |
Why?
| | Electrolytes | 3 | 2005 | 55 | 0.090 |
Why?
| | Glutamates | 3 | 2005 | 57 | 0.090 |
Why?
| | Peptides | 1 | 2015 | 848 | 0.090 |
Why?
| | Quality of Health Care | 1 | 2014 | 573 | 0.080 |
Why?
| | Duodenum | 1 | 2010 | 62 | 0.080 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 849 | 0.080 |
Why?
| | Intra-Abdominal Fat | 1 | 2009 | 77 | 0.080 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2022 | 339 | 0.080 |
Why?
| | Glutathione | 3 | 2005 | 293 | 0.080 |
Why?
| | Down-Regulation | 1 | 2011 | 594 | 0.080 |
Why?
| | Adenosine | 3 | 2005 | 203 | 0.080 |
Why?
| | Magnetic Resonance Angiography | 1 | 2010 | 220 | 0.080 |
Why?
| | United States | 2 | 2021 | 12183 | 0.080 |
Why?
| | Enzyme Replacement Therapy | 2 | 2018 | 10 | 0.070 |
Why?
| | Germ-Line Mutation | 2 | 2019 | 130 | 0.070 |
Why?
| | Child, Preschool | 2 | 2019 | 9116 | 0.070 |
Why?
| | Diabetic Retinopathy | 2 | 2006 | 149 | 0.070 |
Why?
| | Morbidity | 2 | 2019 | 280 | 0.070 |
Why?
| | ErbB Receptors | 1 | 2010 | 554 | 0.070 |
Why?
| | Gliclazide | 1 | 2007 | 1 | 0.070 |
Why?
| | Clinical Decision-Making | 2 | 2020 | 268 | 0.070 |
Why?
| | Consensus | 2 | 2020 | 537 | 0.070 |
Why?
| | Tumor Microenvironment | 2 | 2020 | 430 | 0.070 |
Why?
| | Cytotoxicity, Immunologic | 2 | 2018 | 195 | 0.070 |
Why?
| | Arterial Occlusive Diseases | 1 | 2007 | 74 | 0.070 |
Why?
| | Blood Loss, Surgical | 1 | 2007 | 84 | 0.070 |
Why?
| | Equilibrative Nucleoside Transporter 1 | 1 | 2006 | 13 | 0.070 |
Why?
| | C-Peptide | 1 | 2007 | 138 | 0.070 |
Why?
| | Alcohol Drinking | 2 | 2013 | 651 | 0.070 |
Why?
| | Extracorporeal Circulation | 1 | 2006 | 14 | 0.070 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2010 | 636 | 0.060 |
Why?
| | Hepatic Veins | 1 | 2006 | 29 | 0.060 |
Why?
| | Lacerations | 1 | 2006 | 27 | 0.060 |
Why?
| | Vena Cava, Inferior | 1 | 2006 | 56 | 0.060 |
Why?
| | Transplantation, Autologous | 1 | 2006 | 176 | 0.060 |
Why?
| | Neovascularization, Pathologic | 1 | 2007 | 281 | 0.060 |
Why?
| | Smoking | 2 | 2013 | 1383 | 0.060 |
Why?
| | Abdominal Injuries | 1 | 2006 | 108 | 0.060 |
Why?
| | Contrast Media | 3 | 2016 | 345 | 0.060 |
Why?
| | Jehovah's Witnesses | 1 | 2004 | 1 | 0.060 |
Why?
| | Bezoars | 1 | 2004 | 4 | 0.060 |
Why?
| | RNA, Messenger | 5 | 2011 | 2553 | 0.060 |
Why?
| | Intestinal Obstruction | 1 | 2004 | 40 | 0.060 |
Why?
| | Biopsy | 3 | 2019 | 1036 | 0.060 |
Why?
| | Splenectomy | 1 | 2024 | 52 | 0.060 |
Why?
| | Cystectomy | 1 | 2003 | 32 | 0.050 |
Why?
| | Chemotaxis | 1 | 2004 | 130 | 0.050 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2023 | 28 | 0.050 |
Why?
| | Child | 3 | 2019 | 18415 | 0.050 |
Why?
| | Ileum | 1 | 2003 | 90 | 0.050 |
Why?
| | Intestine, Small | 1 | 2004 | 122 | 0.050 |
Why?
| | Antioxidants | 1 | 2007 | 530 | 0.050 |
Why?
| | Postoperative Period | 2 | 2019 | 289 | 0.050 |
Why?
| | Intraoperative Complications | 1 | 2004 | 122 | 0.050 |
Why?
| | Lymphatic Metastasis | 1 | 2024 | 275 | 0.050 |
Why?
| | Wounds, Nonpenetrating | 1 | 2006 | 256 | 0.050 |
Why?
| | Gastrectomy | 1 | 2023 | 82 | 0.050 |
Why?
| | ROC Curve | 2 | 2014 | 442 | 0.050 |
Why?
| | Propylamines | 1 | 2022 | 11 | 0.050 |
Why?
| | Stents | 2 | 2022 | 475 | 0.050 |
Why?
| | Genetic Testing | 1 | 2005 | 381 | 0.050 |
Why?
| | Carbohydrates | 1 | 2022 | 55 | 0.050 |
Why?
| | Cell Line, Tumor | 3 | 2018 | 2710 | 0.050 |
Why?
| | Creatinine | 4 | 2004 | 425 | 0.050 |
Why?
| | Urinary Bladder | 1 | 2003 | 162 | 0.050 |
Why?
| | Azathioprine | 1 | 2001 | 49 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2021 | 4694 | 0.050 |
Why?
| | Vascular Diseases | 1 | 2004 | 230 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2001 | 77 | 0.050 |
Why?
| | Necrosis | 1 | 2022 | 211 | 0.050 |
Why?
| | Urinary Bladder Neoplasms | 1 | 2003 | 196 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2022 | 3003 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 923 | 0.050 |
Why?
| | Mice | 3 | 2022 | 14869 | 0.050 |
Why?
| | Ephrin-B2 | 1 | 2021 | 36 | 0.050 |
Why?
| | Retroperitoneal Space | 3 | 2005 | 15 | 0.050 |
Why?
| | Steroids | 1 | 2001 | 144 | 0.050 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2023 | 203 | 0.050 |
Why?
| | Medical Oncology | 1 | 2022 | 229 | 0.050 |
Why?
| | Hyperplasia | 1 | 2021 | 163 | 0.040 |
Why?
| | Microbial Viability | 1 | 2021 | 79 | 0.040 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 64 | 0.040 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2005 | 520 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2020 | 38 | 0.040 |
Why?
| | Margins of Excision | 1 | 2019 | 29 | 0.040 |
Why?
| | Capecitabine | 1 | 2019 | 45 | 0.040 |
Why?
| | Florida | 1 | 2020 | 73 | 0.040 |
Why?
| | Secretin | 2 | 2010 | 4 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 33 | 0.040 |
Why?
| | Republic of Korea | 1 | 2019 | 27 | 0.040 |
Why?
| | Hyperthermia, Induced | 1 | 2020 | 65 | 0.040 |
Why?
| | Asia | 1 | 2019 | 53 | 0.040 |
Why?
| | Treatment Failure | 3 | 2005 | 331 | 0.040 |
Why?
| | International Cooperation | 1 | 2020 | 171 | 0.040 |
Why?
| | Acute Disease | 1 | 2022 | 911 | 0.040 |
Why?
| | Cell Death | 1 | 2021 | 323 | 0.040 |
Why?
| | Cells, Cultured | 3 | 2016 | 3886 | 0.040 |
Why?
| | Area Under Curve | 1 | 2019 | 274 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 630 | 0.040 |
Why?
| | Aquaporin 1 | 1 | 2018 | 3 | 0.040 |
Why?
| | Radiotherapy | 1 | 2019 | 176 | 0.040 |
Why?
| | Stromal Cells | 1 | 2019 | 97 | 0.040 |
Why?
| | Cause of Death | 3 | 2005 | 361 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 698 | 0.040 |
Why?
| | Pancreatic Elastase | 1 | 2018 | 66 | 0.040 |
Why?
| | Congresses as Topic | 1 | 2020 | 195 | 0.040 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2010 | 25 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2018 | 39 | 0.040 |
Why?
| | Multivariate Analysis | 2 | 2013 | 1430 | 0.040 |
Why?
| | Preoperative Period | 1 | 2018 | 103 | 0.040 |
Why?
| | Anastomotic Leak | 1 | 2017 | 27 | 0.040 |
Why?
| | Observer Variation | 1 | 2018 | 296 | 0.040 |
Why?
| | Robotic Surgical Procedures | 1 | 2019 | 85 | 0.040 |
Why?
| | Betacoronavirus | 1 | 2020 | 250 | 0.040 |
Why?
| | Lymph Nodes | 1 | 2019 | 419 | 0.040 |
Why?
| | Patient Safety | 1 | 2020 | 277 | 0.040 |
Why?
| | Diabetic Nephropathies | 3 | 2005 | 234 | 0.040 |
Why?
| | Perioperative Care | 1 | 2018 | 127 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2010 | 740 | 0.030 |
Why?
| | Intestinal Neoplasms | 1 | 2016 | 24 | 0.030 |
Why?
| | Cell Movement | 1 | 2021 | 869 | 0.030 |
Why?
| | Cholangiocarcinoma | 1 | 2016 | 38 | 0.030 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 228 | 0.030 |
Why?
| | Drug Therapy, Combination | 3 | 2004 | 951 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 633 | 0.030 |
Why?
| | Principal Component Analysis | 1 | 2016 | 175 | 0.030 |
Why?
| | Nutritional Status | 1 | 2018 | 287 | 0.030 |
Why?
| | Feces | 1 | 2018 | 373 | 0.030 |
Why?
| | Transplantation, Homologous | 2 | 2010 | 377 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2016 | 136 | 0.030 |
Why?
| | Animals | 3 | 2022 | 31706 | 0.030 |
Why?
| | Vitamins | 1 | 2017 | 151 | 0.030 |
Why?
| | Research Design | 1 | 2021 | 928 | 0.030 |
Why?
| | Extracellular Matrix | 1 | 2019 | 436 | 0.030 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 98 | 0.030 |
Why?
| | Cell Line | 1 | 2021 | 2637 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2018 | 1083 | 0.030 |
Why?
| | Radiation Dosage | 1 | 2016 | 133 | 0.030 |
Why?
| | Anatomy, Cross-Sectional | 1 | 2014 | 11 | 0.030 |
Why?
| | Bacteria | 1 | 2021 | 725 | 0.030 |
Why?
| | Kidney Failure, Chronic | 3 | 2004 | 489 | 0.030 |
Why?
| | Intraoperative Care | 1 | 2014 | 34 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2017 | 740 | 0.030 |
Why?
| | Antigens, Neoplasm | 1 | 2016 | 222 | 0.030 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2014 | 72 | 0.030 |
Why?
| | Biomedical Research | 1 | 2019 | 585 | 0.030 |
Why?
| | Immunologic Memory | 1 | 2016 | 313 | 0.030 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 445 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2010 | 1842 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1469 | 0.030 |
Why?
| | Cytokines | 2 | 2016 | 1841 | 0.030 |
Why?
| | Indole Alkaloids | 1 | 2013 | 9 | 0.030 |
Why?
| | Drug Administration Schedule | 2 | 2005 | 718 | 0.030 |
Why?
| | Drug Interactions | 2 | 2005 | 338 | 0.030 |
Why?
| | Peptic Ulcer | 1 | 2013 | 14 | 0.030 |
Why?
| | Histocompatibility Testing | 2 | 2004 | 116 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 287 | 0.030 |
Why?
| | Hypoxia | 1 | 2019 | 958 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2013 | 75 | 0.030 |
Why?
| | Pandemics | 1 | 2020 | 1317 | 0.020 |
Why?
| | Safety | 2 | 2004 | 297 | 0.020 |
Why?
| | Postoperative Care | 1 | 2013 | 222 | 0.020 |
Why?
| | Lymphocyte Activation | 1 | 2016 | 1037 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 1214 | 0.020 |
Why?
| | Anti-Bacterial Agents | 1 | 2021 | 1481 | 0.020 |
Why?
| | Carcinoma, Renal Cell | 1 | 2013 | 168 | 0.020 |
Why?
| | Lung | 1 | 2023 | 3561 | 0.020 |
Why?
| | Microsatellite Repeats | 1 | 2011 | 136 | 0.020 |
Why?
| | In Situ Hybridization | 1 | 2011 | 292 | 0.020 |
Why?
| | Korea | 1 | 2010 | 8 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2001 | 1727 | 0.020 |
Why?
| | Cell Growth Processes | 1 | 2010 | 51 | 0.020 |
Why?
| | Odds Ratio | 1 | 2013 | 953 | 0.020 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 57 | 0.020 |
Why?
| | Blood Glucose | 3 | 2004 | 1828 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2010 | 182 | 0.020 |
Why?
| | Thyroid Neoplasms | 1 | 2013 | 264 | 0.020 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2010 | 119 | 0.020 |
Why?
| | Edetic Acid | 1 | 2009 | 47 | 0.020 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 327 | 0.020 |
Why?
| | Pyridoxal Phosphate | 1 | 2009 | 20 | 0.020 |
Why?
| | PTEN Phosphohydrolase | 1 | 2010 | 140 | 0.020 |
Why?
| | Tetrazolium Salts | 1 | 2008 | 18 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 398 | 0.020 |
Why?
| | Thiazoles | 1 | 2008 | 110 | 0.020 |
Why?
| | Surgical Procedures, Operative | 1 | 2010 | 207 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2010 | 498 | 0.020 |
Why?
| | Epigenesis, Genetic | 1 | 2011 | 520 | 0.020 |
Why?
| | Recurrence | 1 | 2010 | 935 | 0.020 |
Why?
| | bcl-2-Associated X Protein | 1 | 2007 | 45 | 0.020 |
Why?
| | Glyburide | 1 | 2007 | 35 | 0.020 |
Why?
| | Mutation | 1 | 2017 | 3346 | 0.020 |
Why?
| | Colorectal Neoplasms | 1 | 2013 | 615 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 410 | 0.020 |
Why?
| | Deoxycytidine Kinase | 1 | 2006 | 3 | 0.020 |
Why?
| | Ribonucleoside Diphosphate Reductase | 1 | 2006 | 4 | 0.020 |
Why?
| | Fluorescein Angiography | 1 | 2006 | 102 | 0.020 |
Why?
| | Motorcycles | 1 | 2006 | 5 | 0.020 |
Why?
| | Choledochostomy | 1 | 2006 | 11 | 0.020 |
Why?
| | Budd-Chiari Syndrome | 1 | 2006 | 6 | 0.020 |
Why?
| | Tyrosine | 1 | 2007 | 214 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2013 | 921 | 0.020 |
Why?
| | 5'-Nucleotidase | 1 | 2006 | 35 | 0.020 |
Why?
| | Phosphorylation | 1 | 2010 | 1569 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2007 | 213 | 0.020 |
Why?
| | Proteomics | 1 | 2011 | 836 | 0.020 |
Why?
| | Cytidine Deaminase | 1 | 2006 | 58 | 0.020 |
Why?
| | Hemorrhage | 1 | 2010 | 620 | 0.020 |
Why?
| | Antilymphocyte Serum | 1 | 2005 | 60 | 0.020 |
Why?
| | Economics, Pharmaceutical | 1 | 2005 | 10 | 0.020 |
Why?
| | Hepatectomy | 1 | 2006 | 119 | 0.020 |
Why?
| | Blood Group Incompatibility | 1 | 2005 | 14 | 0.020 |
Why?
| | Fatal Outcome | 1 | 2006 | 284 | 0.020 |
Why?
| | Methylprednisolone | 1 | 2005 | 81 | 0.020 |
Why?
| | Maximum Tolerated Dose | 1 | 2005 | 183 | 0.020 |
Why?
| | Accidents, Traffic | 1 | 2006 | 170 | 0.010 |
Why?
| | Visual Acuity | 1 | 2006 | 274 | 0.010 |
Why?
| | Isoantibodies | 1 | 2005 | 57 | 0.010 |
Why?
| | Glycerolphosphate Dehydrogenase | 1 | 2004 | 4 | 0.010 |
Why?
| | Intraocular Pressure | 1 | 2006 | 276 | 0.010 |
Why?
| | Fructose-Bisphosphate Aldolase | 1 | 2004 | 7 | 0.010 |
Why?
| | Glucokinase | 1 | 2004 | 13 | 0.010 |
Why?
| | Pyruvate Kinase | 1 | 2004 | 19 | 0.010 |
Why?
| | DNA Primers | 1 | 2005 | 510 | 0.010 |
Why?
| | Diabetic Neuropathies | 1 | 2005 | 79 | 0.010 |
Why?
| | Pharmacogenetics | 1 | 2005 | 149 | 0.010 |
Why?
| | Transcriptional Activation | 1 | 2006 | 337 | 0.010 |
Why?
| | Renal Circulation | 1 | 2004 | 53 | 0.010 |
Why?
| | Tissue Culture Techniques | 1 | 2004 | 66 | 0.010 |
Why?
| | Tumor Suppressor Proteins | 1 | 2006 | 282 | 0.010 |
Why?
| | Kidney Function Tests | 1 | 2003 | 140 | 0.010 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2003 | 53 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 2005 | 249 | 0.010 |
Why?
| | Cell Separation | 1 | 2004 | 291 | 0.010 |
Why?
| | Respiratory Insufficiency | 1 | 2006 | 290 | 0.010 |
Why?
| | Obesity, Morbid | 1 | 2005 | 197 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1016 | 0.010 |
Why?
| | Thrombosis | 1 | 2005 | 298 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 2013 | 1862 | 0.010 |
Why?
| | Base Sequence | 1 | 2005 | 2114 | 0.010 |
Why?
| | Glucocorticoids | 1 | 2005 | 532 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1421 | 0.010 |
Why?
| | Ischemia | 1 | 2004 | 362 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1012 | 0.010 |
Why?
| | Blood Pressure | 1 | 2005 | 1538 | 0.010 |
Why?
| | T-Lymphocytes | 1 | 2005 | 1737 | 0.010 |
Why?
| | Hypoglycemic Agents | 1 | 2005 | 1013 | 0.010 |
Why?
| | Body Mass Index | 1 | 2004 | 1959 | 0.010 |
Why?
|
|
Del Chiaro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|